Skip to Main Content
Try STAT+ TODAY
Trending:
Coronavirus
Health
Biotech
First Opinion
The Readout

Moderna’s patent problems & clocking the CRISPR race

  • Damian Garde
  • Meghana Keshavan

By Damian Garde and Meghana Keshavan May 17, 2017

Reprints
The READOUT
Alex Hogan/STAT

The Readout for May 17, 2017

About the Authors Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Meghana Keshavan

Meghana Keshavan

Biotech Correspondent

Meghana covers biotech and contributes to The Readout newsletter.

Trending
cytokine storm cell signalling
FDA rejects antidepressant seen as possible Covid-19 treatment
FDA rejects antidepressant seen as possible Covid-19 treatment
Eli Lilly headquarters
FDA approves Lilly diabetes drug that analysts expect to…
FDA approves Lilly diabetes drug that analysts expect to be a big seller
What the current spike in Covid-19 cases could say…
What the current spike in Covid-19 cases could say about the coronavirus’ future
Recommended
The READOUT
Regeneron targets obesity, a new microbiome deal, & comparing…
Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
The READOUT
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries…
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
The READOUT
Docs disagree with FDA on Aduhelm, Swiss giants pinch…
Docs disagree with FDA on Aduhelm, Swiss giants pinch pennies, & one SPAC makes it rain

Recommended Stories

The READOUT
The Readout

Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs

By Meghana Keshavan

The READOUT
The Readout

Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue

By Damian Garde

Biotech

Police reports detailing Seagen CEO’s arrest raise questions about biotech’s response

By Damian Garde

Biotech

A new biotech investment firm, headed by a pair of noteworthy VCs, seeks to ‘free the founders’

By Allison DeAngelis

Adam's Take

It took years, but the failure of Northwest Bio’s brain cancer vaccine is now in the open

By Adam Feuerstein